21CFR CONTROLLED SUBSTANCES ACT

PART 1310--RECORDS

 

 

 

 

[Code of Federal Regulations]

[Title 21, Volume 9, Parts 1300 to end]

[Revised as of April 1, 1998]

From the U.S. Government Printing Office via GPO Access

[CITE: 21CFR1310]

 

[Page 107-117]

TITLE 21-FOOD AND DRUGS

CHAPTER II--DRUG ENFORCEMENT ADMINISTRATION, DEPARTMENT OF JUSTICE

PART 1310--RECORDS AND REPORTS OF LISTED CHEMICALS AND CERTAIN MACHINES

 

Sec.

1310.01 Definitions.

1310.02 Substances covered.

1310.03 Persons required to keep records and file reports.

1310.04 Maintenance of records.

1310.05 Reports.

1310.06 Content of records and reports.

1310.07 Proof of identity.

1310.08 Excluded transactions.

1310.09 Temporary exemption from registration.

1310.10 Removal of the exemption of drugs distributed under the Food,

Drug and Cosmetic Act.

1310.11 Reinstatement of exemption for drug products distributed under

the Food, Drug and Cosmetic Act.

1310.14 Exemption of drug products containing ephedrine and

therapeutically significant quantities of another active

medicinal ingredient.

1310.15 Exempt drug products containing ephedrine and therapeutically

significant quantities of another active medicinal ingredient.

 

Authority: 21 U.S.C. 802, 830, 871(b).

 

Source: 54 FR 31665, Aug. 1, 1989, unless otherwise noted.

 

Sec. 1310.01 Definitions.

 

Any term used in this part shall have the definition set forth in

section 102 of the Act (21 U.S.C. 802) or part 1300 of this chapter.

[62 FR 13968, Mar. 24, 1997]

 

Sec. 1310.02 Substances covered.

 

The following chemicals have been specifically designated by the

Administrator of the Drug Enforcement Administration as the listed

chemicals subject to the provisions of this part and parts 1309 and 1313

of this chapter. Each chemical has been assigned the DEA Chemical Code

Number set forth opposite it.

(a) List I chemicals

 

(1) Anthranilic acid, its esters, and its salts.....................8530

(2) Benzyl cyanide..................................................8735

(3) Ephedrine, its salts, optical isomers, and salts of optical isomers

8113

(4) Ergonovine and its salts........................................8675

(5) Ergotamine and its salts........................................8676

(6) N-Acetylanthranilic acid, its esters, and its salts.............8522

(7) Norpseudoephedrine, its salts, optical isomers, and salts of optical

isomers.............................................................8317

(8) Phenylacetic acid, its esters, and its salts....................8791

(9) Phenylpropanolamine, its salts, optical isomers, and salts of

optical isomers.....................................................1225

(10) Piperidine and its salts.......................................2704

(11) Pseudoephedrine, its salts, optical isomers, and salts of optical

isomers.............................................................8112

(12) 3,4-Methylenedioxyphenyl-2-propanone...........................8502

(13) Methylamine and its salts......................................8520

(14) Ethylamine and its salts.......................................8678

(15) Propionic anhydride............................................8328

(16) Isosafrole.....................................................8704

(17) Safrole........................................................8323

(18) Piperonal......................................................8750

 

[[Page 108]]

 

(19) N-Methylephedrine, its salts, optical isomers, and salts of optical

isomers (N-Methylephedrine).........................................8115

(20) N-Methylpseudoephedrine, its salts, optical isomers, and salts of

optical isomers.....................................................8119

(21) Hydriodic Acid.................................................6695

(22) Benzaldehyde...................................................8256

(23) Nitroethane....................................................6724

 

(b) List II chemicals:

 

(1) Acetic anhydride................................................8519

(2) Acetone.........................................................6532

(3) Benzyl chloride.................................................8570

(4) Ethyl ether.....................................................6584

(5) Potassium permanganate..........................................6579

(6) 2-Butanone (or Methyl Ethyl Ketone or MEK)......................6714

(7) Toluene.........................................................6594

(8) Hydrochloric acid...............................................6545

(9) Sulfuric acid...................................................6552

(10) Methyl Isobutyl Ketone (MIBK)..................................6715

 

(c) The Administrator may add or delete a substance as a listed

chemical by publishing a final rule in the Federal Register following a

proposal which shall be published at least 30 days prior to the final

rule.

(d) Any person may petition the Administrator to have any substance

added or deleted from paragraphs (a) or (b) of this section.

(e) Any petition under this section shall contain the following

information:

(1) The name and address of the petitioner;

(2) The name of the chemical to which the petition pertains;

(3) The name and address of the manufacturer(s) of the chemical (if

known);

(4) A complete statement of the facts which the petitioner believes

justifies the addition or deletion of the substance from paragraphs (a)

or (b) of this section;

(5) The date of the petition.

(f) The Administrator may require the petitioner to submit such

documents or written statements of fact relevant to the petition as he

deems necessary in making a determination.

(g) Within a reasonable period of time after the receipt of the

petition, the Administrator shall notify the petitioner of his decision

and the reason therefor. The Administrator need not accept a petition if

any of the requirements prescribed in paragraph (e) of this section or

requested pursuant to paragraph (f) of this section are lacking or are

not clearly set forth as to be readily understood. If the petitioner

desires, he may amend and resubmit the petition to meet the requirements

of paragraphs (e) and (f) of this section.

(h) If a petition is granted or the Administrator, upon his own

motion, proposes to add or delete substances as listed chemicals as set

forth in paragraph (c) of this section, he shall issue and publish in

the Federal Register a proposal to add or delete a substance as a listed

chemical. The Administrator shall permit any interested person to file

written comments regarding the proposal within 30 days of the date of

publication of his order in the Federal Register. The Administrator will

consider any comments filed by interested persons and publish a final

rule in accordance with his decision in the matter.

[54 FR 31665, Aug. 1, 1989, as amended at 56 FR 48733, Sept. 26, 1991;

57 FR 43615, Sept. 22, 1992; 60 FR 19510, Apr. 19, 1995; 60 FR 32460,

June 22, 1995; 62 FR 5917, Feb. 10, 1997]

 

Sec. 1310.03 Persons required to keep records and file reports.

 

(a) Each regulated person who engages in a regulated transaction

involving a listed chemical, a tableting machine, or an encapsulating

machine shall keep a record of the transaction as specified by

Sec. 1310.04 and file reports as specified by Sec. 1310.05. However, a

non-regulated person who acquires listed chemicals for internal

consumption or ``end use'' and becomes a regulated person by virtue of

infrequent or rare distribution of a listed chemical from inventory,

shall not be required to maintain receipt records of listed chemicals

under this section.

(b) Each regulated person who manufactures a List I or List II

chemical shall file reports regarding such manufacture as specified in

Section 1310.05.

[54 FR 31665, Aug. 1, 1989, as amended at 56 FR 8277, Feb. 28, 1991; 61

FR 14023, Mar. 29, 1996]

 

Sec. 1310.04 Maintenance of records.

 

(a) Every record required to be kept subject to Sec. 1310.03 for a

List I chemical, a tableting machine, or an encapsulating machine shall

be kept by the

 

[[Page 109]]

 

regulated person for 2 years after the date of the transaction.

(b) Every record required to be kept subject to Section 1310.03 for

List II chemical shall be kept by the regulated person for two years

after the date of the transaction.

(c) A record under this section shall be kept at the regulated

person's place of business where the transaction occurred, except that

records may be kept at a single, central location of the regulated

person if the regulated person has notified the Administration of the

intention to do so. Written notification must be submitted by registered

or certified mail, return receipt requested, to the Special Agent in

Charge of the DEA Divisional Office for the area in which the records

are required to be kept.

(d) The records required to be kept under this section shall be

readily retrievable and available for inspection and copying by

authorized employees of the Administration under the provisions of 21

U.S.C. 880.

(e) The regulated person with more than one place of business where

records are required to be kept shall devise a system to detect any

party purchasing from several individual locations of the regulated

person thereby seeking to avoid the application of the cumulative

threshold or evading the requirements of the Act.

(f) For those listed chemicals for which thresholds have been

established, the quantitative threshold or the cumulative amount for

multiple transactions within a calendar month, to be utilized in

determining whether a receipt, sale, importation or exportation is a

regulated transaction is as follows:

(1) List I Chemicals:

 

------------------------------------------------------------------------

Chemical Threshold by base weight

------------------------------------------------------------------------

(i) Anthranilic acid and its salts... 30 kilograms.

(ii) Benzyl cyanide.................. 1 kilogram.

(iii) Ergonovine and its salts....... 10 grams.

(iv) Ergotamine and its salts........ 20 grams.

(v) N-Acetylanthranilic acid and its 40 kilograms

salts.

(vi) Norpseudoephedrine, its salts, 2.5 kilograms.

optical isomers, and salts of

optical isomers.

(vii) Phenylacetic acid and its salts 1 kilogram.

(viii) Phenylpropanolamine, its 2.5 kilograms.

salts, optical isomers, and salts of

optical isomers.

(ix) Piperidine and its salts........ 500 grams.

(x) Pseudoephedrine, its salts, 1 kilogram

optical isomers, and salts of

optical isomers.

(xi) 3, 4-Methylenedioxyphenyl-2- 4 kilograms.

propanone.

(xii) Methylamine and its salts...... 1 kilogram.

(xiii) Ethylamine and its salts...... 1 kilogram.

(xiv) Propionic anhydride............ 1 gram.

(xv) Isosafrole...................... 4 kilograms.

(xvi) Safrole........................ 4 kilograms.

(xvii) Piperonal..................... 4 kilograms.

(xviii) N-Methylephedrine, its salts, 1 kilogram.

optical isomers, and salts of

optical isomers.

(xix) N-Methylpseudoephedrine, its 1 kilogram.

salts, optical isomers, and salts of

optical isomers.

(xx) Hydriotic acid (57%)............ 1.7 kilograms (or 1 liter by

volume).

(xxi) Benzaldehyde................... 4 Kilograms.

(xxii) Nitroethane................... 2.5 Kilograms.

------------------------------------------------------------------------

 

(2) List II Chemicals:

(i) Imports and Exports

 

----------------------------------------------------------------------------------------------------------------

Chemical Threshold by volume Threshold by weight

----------------------------------------------------------------------------------------------------------------

(A) Acetic anhydride................... 250 gallons........................ 1,023 kilograms.

(B) Acetone............................ 500 gallons........................ 1,500 kilograms.

(C) Benzyl chloride.................... N/A................................ 4 kilograms.

(D) Ethyl ether........................ 500 gallons........................ 1,364 kilograms.

(E) Potassium permanganate............. N/A................................ 500 kilograms.

(F) 2-Butanone (MEK)................... 500 gallons........................ 1,455 kilograms.

(G) Toluene............................ 500 gallons........................ 1,591 kilograms.

----------------------------------------------------------------------------------------------------------------

 

(ii) Domestic Sales

 

[[Page 110]]

 

 

 

----------------------------------------------------------------------------------------------------------------

Chemical Threshold by volume Threshold by weight

----------------------------------------------------------------------------------------------------------------

(A) Acetic anhydride................... 250 gallons........................ 1,023 kilograms.

(B) Acetone............................ 50 gallons......................... 150 kilograms.

(C) Benzyl chloride.................... N/A................................ 1 kilogram.

(D) Ethyl ether........................ 50 gallons......................... 135.8 kilograms.

(E) Potassium permanganate............. N/A................................ 55 kilograms.

(F) 2-Butanone (MEK)................... 50 gallons......................... 145 kilograms.

(G) Toluene............................ 50 gallons......................... 159 kilograms.

----------------------------------------------------------------------------------------------------------------

 

(iii) The cumulative threshold is not applicable to domestic sales

of Acetone, 2-Butanone (MEK), and Toluene.

(iv) Exports, transshipments and international transactions to

Designated Countries set forth in Sec. 1310.08(b)

(v) Export and International Transactions to Designated Countries,

and Importations for Transshipment or Transfer to Designated Countries

 

------------------------------------------------------------------------

Threshold by

Chemical volume Threshold by weight

------------------------------------------------------------------------

(A) Methyl Isobutyl Ketone 500 gallons....... 1523 kilograms.

(MIBK).

(B) Reserved.

------------------------------------------------------------------------

 

(g) For listed chemicals for which no thresholds have been

established, the size of the transaction is not a factor in determining

whether the transaction meets the definition of a regulated transaction

as set forth in Sec. 1310.01(f). All such transactions, regardless of

size, are subject to recordkeeping and reporting requirements as set

forth in this part 1310 and notification provisions as set forth in part

1313 of this chapter.

(1) Listed Chemicals For Which No Thresholds Have Been Established:

(i) Ephedrine, its salts, optical isomers, and salts of optical

isomers

(ii) [Reserved]

(2) [Reserved]

[54 FR 31665, Aug. 1, 1989, as amended at 56 FR 48733, Sept. 26, 1991;

57 FR 43615, Sept. 22, 1992; 59 FR 51367, Oct. 11, 1994; 60 FR 19510,

Apr. 19, 1995; 60 FR 32460, June 22, 1995; 60 FR 42436, Aug. 16, 1995;

62 FR 5917, Feb. 10, 1997]

 

Sec. 1310.05 Reports.

 

(a) Each regulated person shall report to the Special Agent in

Charge of the DEA Divisional Office for the area in which the regulated

person making the report is located, as follows:

(1) Any regulated transaction involving an extraordinary quantity of

a listed chemical, an uncommon method of payment or delivery, or any

other circumstance that the regulated person believes may indicate that

the listed chemical will be used in violation of this part.

(2) Any proposed regulated transaction with a person whose

description or other identifying characteristic the Administration has

previously furnished to the regulated person.

(3) Any unusual or excessive loss or disappearance of a listed

chemical under the control of the regulated person. The regulated person

responsible for reporting a loss in-transit is the supplier.

(4) Any domestic regulated transaction in a tableting machine or an

encapsulating machine.

(b) Each report submitted pursuant to paragraph (a) of this section

shall, whenever possible, be made orally to the DEA Divisional Office

for the area in which the regulated person making the report is located

at the earliest practicable opportunity after the regulated person

becomes aware of the circumstances involved and as much in advance of

the conclusion of the transaction as possible. Written reports of

transactions listed in paragraphs (a)(1), (a)(3) and (a)(4) of this

section will subsequently be filed as set forth in Sec. 1310.06 within

15 days after the regulated person becomes aware of the circumstances of

the event. A transaction may not be completed with a person whose

description or identifying characteristic has previously been furnished

to the regulated person by the Administration unless the transaction is

approved by the Administration.

(c) Each regulated person who imports or exports a tableting

machine, or encapsulation machine, shall file a report (not a 486) of

such importation or exportation with the Administration at the following

address on or before the date of importation or exportation:

 

[[Page 111]]

 

Drug Enforcement Administration, P.O. Box 28346, Washington, DC 20038.

In order to facilitate the importation or exportation of any tableting

machine or encapsulating machine and implement the purpose of the Act,

regulated persons may wish to report to the Administration as far in

advance as possible. A copy of the report may be transmitted directly to

the Drug Enforcement Administration through electronic facsimile media.

Any tableting machine or encapsulating machine may be imported or

exported if that machine is needed for medical, commercial, scientific,

or other legitimate uses. However, an importation or exportation of a

tableting machine or encapsulating machine may not be completed with a

person whose description or identifying characteristic has previously

been furnished to the regulated person by the Administration unless the

transaction is approved by the Administration.

(d) Each regulated bulk manufacturer of a listed chemical shall

submit manufacturing, inventory and use data on an annual basis as set

forth in Sec. 1310.06(h). This data shall be submitted annually to the

Drug and Chemical Evaluation Section, Drug Enforcement Administration

(DEA), Washington, D.C. 20537, on or before the 15th day of March of the

year immediately following the calendar year for which submitted. A

business entity which manufactures a listed chemical may elect to report

separately by individual location or report as an aggregate amount for

the entire business entity provided that they inform the DEA of which

method they will use. This reporting requirement does not apply to drug

or other products which are exempted under Secs. 1310.01(f)(1)(iv) or

1310.01(f)(1)(v) except as set forth in Sec. 1310.06(h)(5). Bulk

manufacturers that produce a listed chemical solely for internal

consumption shall not be required to report for that listed chemical.

For purposes of these reporting requirements, internal consumption shall

consist of any quantity of a listed chemical otherwise not available for

further resale or distribution. Internal consumption shall include (but

not be limited to) quantities used for quality control testing,

quantities consumed in-house or production losses. Internal consumption

does not include the quantities of a listed chemical consumed in the

production of exempted products. If an existing standard industry report

contains the information required in Sec. 1310.06(h) and such

information is separate or readily retrievable from the report, that

report may be submitted in satisfaction of this requirement. Each report

shall be submitted to the DEA under company letterhead and signed by an

appropriate, responsible official. For purposes of this paragraph only,

the term regulated bulk manufacturer of a listed chemical means a person

who manufactures a listed chemical by means of chemical synthesis or by

extraction from other substances. The term bulk manufacturer does not

include persons whose sole activity consists of the repackaging or

relabeling of listed chemical products or the manufacture of drug dosage

form products which contain a listed chemical.

[54 FR 31665, Aug. 1, 1989, as amended at 57 FR 2461, Jan. 22, 1992; 61

FR 14024, Mar. 29, 1996; 61 FR 17958, Apr. 23, 1996; 62 FR 13968, Mar.

24, 1997]

 

Sec. 1310.06 Content of records and reports.

 

(a) Each record required by Sec. 1310.03 shall include the

following:

(1) The name, address, and, if required, DEA registration number of

each party to the regulated transaction.

(2) The date of the regulated transaction.

(3) The name, quantity and form of packaging of the listed chemical

or a description of the tableting machine or encapsulating machine

(including make, model and serial number).

(4) The method of transfer (company truck, picked up by customer,

etc.).

(5) The type of identification used by the purchaser and any unique

number on that identification.

(b) For purposes of this section, normal business records shall be

considered adequate if they contain the information listed in paragraph

(a) of this section and are readily retrievable from other business

records of the regulated person. For prescription drug products,

prescription and hospital

 

[[Page 112]]

 

records kept in the normal course of medical treatment shall be

considered adequate for satisfying the requirements of paragraph (a) of

this section with respect to dispensing to patients, and records

required to be maintained pursuant to the Federal Food and Drug

Administration regulations relating to the distribution of prescription

drugs, as set forth in 21 CFR part 205, shall be considered adequate for

satisfying the requirements of paragraph (a) of this section with

respect to distributions.

(c) Each report required by Section 1310.05(a) shall include the

information as specified by Section 1310.06(a) and, where obtainable,

the registration number of the other party, if such party is registered.

A report submitted pursuant to Sec. 1310.05(a)(1) or (a)(4) must also

include a description of the circumstances leading the regulated person

to make the report, such as the reason that the method of payment was

uncommon or the loss unusual. If the report is for a loss or

disappearance under Sec. 1310.05(a)(4), the circumstances of such loss

must be provided (in-transit, theft from premises, etc.)

(d) A suggested format for the reports is provided below:

 

Supplier:

 

Registration Number____________________________________________________

Name___________________________________________________________________

Business Address_______________________________________________________

City___________________________________________________________________

State__________________________________________________________________

Zip____________________________________________________________________

Business Phone_________________________________________________________

 

Purchaser:

 

Registration Number____________________________________________________

Name___________________________________________________________________

Business Address_______________________________________________________

City___________________________________________________________________

State__________________________________________________________________

Zip____________________________________________________________________

Business Phone_________________________________________________________

Identification_________________________________________________________

 

Shipping Address (if different than purchaser Address):

 

Street_________________________________________________________________

City___________________________________________________________________

State__________________________________________________________________

Zip____________________________________________________________________

Date of Shipment_______________________________________________________

Name of Listed Chemical(s)_____________________________________________

Quantity and Form of Packaging_________________________________________

 

Description of Machine:

 

Make___________________________________________________________________

Model__________________________________________________________________

Serial #_______________________________________________________________

Method of Transfer_____________________________________________________

 

If Loss or Disappearance:

 

Date of Loss___________________________________________________________

Type of Loss___________________________________________________________

Description of Circumstances___________________________________________

 

 

Public reporting burden for this collection of information is estimated

to average ten minutes per response, including the time for reviewing

instructions, searching existing data sources, gathering and maintaining

the data needed, and completing and reviewing the collection of

information. Send comments regarding this burden estimate or any other

aspect of this collection of information, including suggestions for

reducing this burden to the Drug Enforcement Administration, Records

Management Section, Washington, D.C. 20537; and to the Office of

Management and Budget, Paperwork Reduction Project No. 1117-0024,

Washington, D.C. 20503.

(e) Each report of an importation of a tableting machine or an

encapsulating machine required by Sec. 1310.05(c) shall include the

following information:

(1) The name, address, telephone number, tdlex number, and, where

available, the facsimile number of the regulated person; the name,

address, telephone number, telex number, and, where available, the

facsimile number of the import broker or forwarding agent, if any:

(2) The description of each machine (including make, model, and

serial number) and the number of machines being received;

(3) The proposed import date, and the first U.S. Customs Port of

Entry; and

(4) The name, address, telephone number, telex number, and, where

available, the facsimile number of the consignor in the foreign country

of exportation.

(f) Each report of an exportation of a tableting machine or an

encapsulating machine required by Sec. 1310.05(c) shall include the

following information:

(1) The name, address, telephone number, telex number, and, where

available, the facsimile number of the regulated person; the name,

address,

 

[[Page 113]]

 

telephone number, telex number, and, where available, the facsimile

number of the export broker, if any;

(2) The description of each machine (including make, model, and

serial number) and the number of machines being shipped;

(3) The proposed export date, the U.S. Customs Port of exportation,

and the foreign Port of Entry; and

(4) The name, address, telephone, telex, and, where available, the

facsimile number of the consignee in the country where the shipment is

destined; the name(s) and address(es) of any intermediate consignee(s).

(g) Declared exports of machines which are refused, rejected, or

otherwise deemed undeliverable may be returned to the U.S. exporter of

record. A brief written report outlining the circumstances must be sent

to the Drug Enforcement Administration, P.O. Box 28346, Washington, DC

20038, following the return within a reasonable time. This provision

does not apply to shipments that have cleared foreign customs, been

delivered, and accepted by the foreign consignee. Returns to third

parties in the United States will be regarded as imports.

(h) Each annual report required by Section 1310.05(d) shall provide

the following information for each listed chemical manufactured:

(1) The name, address and chemical registration number (if any) of

the manufacturer and person to contact for information.

(2) The aggregate quantity of each listed chemical that the company

manufactured during the preceding calendar year.

(3) The year-end inventory of each listed chemical as of the close

of business on the 31st day of December of each year. (For each listed

chemical, if the prior period's ending inventory has not previously been

reported to DEA, this report should also detail the beginning inventory

for the period.) For purposes of this requirement, inventory shall

reflect the quantity of listed chemicals, whether in bulk or non-exempt

product form, held in storage for later distribution. Inventory does not

include waste material for destruction, material stored as an in-process

intermediate or other in-process material.

(4) The aggregate quantity of each listed chemical used for internal

consumption during the preceding calendar year, unless the chemical is

produced solely for internal consumption.

(5) The aggregate quantity of each listed chemical manufactured

which becomes a component of a product exempted from Section

1310.01(f)(1)(iv) or 1310.01(f)(1)(v) during the preceding calendar

year.

(6) Data shall identify the specific isomer, salt or ester when

applicable but quantitative data shall be reported as anhydrous base or

acid in kilogram units of measure.

[54 FR 31665, Aug. 1, 1989, as amended at 57 FR 2462, Jan. 22, 1992; 59

FR 51364, Oct. 11, 1994; 60 FR 32461, June 22, 1995; 61 FR 14024, Mar.

29, 1996; 61 FR 32926, June 26, 1996]

 

Sec. 1310.07 Proof of identity.

 

(a) Each regulated person who engages in a regulated transaction

must identify the other party to the transaction. For domestic

transaction, this shall be accomplished by having the other party

present documents which would verify the identity, or registration

status if a registrant, of the other party to the regulated person at

the time the order is placed. For export transactions, this shall be

accomplished by good faith inquiry through reasonably available research

documents or publicly available information which would indicate the

existence of the foreign customer. No proof of identity is required for

foreign suppliers.

(b) The regulated person must verify the existence and apparent

validity of a business entity ordering a listed chemical, tableting

machine or encapsulating machine. For domestic transactions, this may be

accomplished by such methods as checking the telephone directory, the

local credit bureau, the local Chamber of Commerce or the local Better

Business Bureau, or, if the business entity is a registrant, by

verification of the registration. For export transactions, a good faith

inquiry to verify the existence and apparent validity of a foreign

business entity may be accomplished by such methods as verifying the

business telephone listing through international telephone

 

[[Page 114]]

 

information, the firm's listing in international or foreign national

chemical directories or other commerce directories or trade

publications, confirmation through foreign subsidiaries of the U.S.

regulated person, verification through the country of destination's

embassy Commercial Attache, or official documents provided by the

purchaser which confirm the existence and apparent validity of the

business entity.

(c) When transacting business with a new representative of a firm,

the regulated person must verify the claimed agency status of the

representative.

(d) For sales to individuals or cash purchasers, the type of

documents and other evidence of proof must consist of at least a

signature of the purchaser, a driver's license and one other form of

identification. Any exports to individuals or exports paid in cash are

suspect and should be handled as such. For such exports, the regulated

person shall diligently obtain from the purchaser or independently seek

to confirm clear documentation which proves the person is properly

identified such as through foreign identity documents, driver's license,

passport information and photograph, etc. Any regulated person who fails

to adequately prove the identity of the other party to the transaction

may be subject to the specific penalties provided for violations of law

related to regulated transactions in listed chemicals.

(e) For a new customer who is not an individual or cash customer,

the regulated person shall establish the identity of the authorized

purchasing agent or agents and have on file that person's signature,

electronic password, or other identification. Once the authorized

purchasing agent has been established, the agent list may be updated

annually rather than on each order. The regulated person must ensure

that shipments are not made unless the order is placed by an authorized

agent of record.

(f) With respect to electronic orders, the identity of the purchaser

shall consist of a computer password, identification number or some

other means of identification consistent with electronic orders and with

Sec. 1310.07(e).

[54 FR 31665, Aug. 1, 1989, as amended at 60 FR 32461, June 22, 1995]

 

Sec. 1310.08 Excluded transactions.

 

Pursuant to 21 U.S.C. 802(39)(A)(iii), regulation of the following

transactions has been determined to be unnecessary for the enforcement

of the Chemical Diversion and Trafficking Act and, therefore, they have

been excluded from the definitions of regulated transactions:

(a) Domestic and import transactions of hydrochloric and sulfuric

acids.

(b) Exports, transshipments, and international transactions of

hydrochloric and sulfuric acids, except for exports, transshipments and

international transactions to the following countries:

(1) Argentina

(2) Bolivia

(3) Brazil

(4) Chile

(5) Colombia

(6) Ecuador

(7) French Guiana

(8) Guyana

(9) Panama

(10) Paraguay

(11) Peru

(12) Suriname

(13) Uruguay

(14) Venezuela

(c) Domestic transactions of Methyl Isobutyl Ketone (MIBK).

(d) Import transactions of Methyl Isobutyl Ketone (MIBK) destined

for the United States.

(e) Export transactions, international transactions, and import

transactions for transshipment or transfer of Methyl Isobutyl Ketone

(MIBK) destined for Canada or any country outside of the Western

Hemisphere.

[57 FR 43615, Sept. 22, 1992, as amended at 60 FR 19510, Apr. 19, 1995;

60 FR 32461, June 22, 1995; 62 FR 13968, Mar. 24, 1997]

 

Sec. 1310.09 Temporary exemption from registration.

 

(a) Each person required by section 302 of the act (21 U.S.C. 822)

to obtain a registration to distribute, import, or export a combination

ephedrine product is temporarily exempted from the

 

[[Page 115]]

 

registration requirement, provided that the person submits a proper

application for registration on or before July 12, 1997. The exemption

will remain in effect for each person who has made such application

until the Administration has approved or denied that application. This

exemption applies only to registration; all other chemical control

requirements set forth in parts 1309, 1310, and 1313 of this chapter

remain in full force and effect.

(b) Each person required by section 302 of the act (21 U.S.C. 822)

to obtain a registration to distribute, import, or export a drug product

that contains pseudoephedrine or phenylpropanolamine that is regulated

pursuant to Sec. 1300.02(b)(28)(1)(D) of this chapter is temporarily

exempted from the registration requirement, provided that the person

submits a proper application for registration on or before December 3,

1997. The exemption will remain in effect for each person who has made

such application until the Administration has approved or denied that

application. This exemption applies only to registration; all other

chemical control requirements set forth in parts 1309, 1310, and 1313 of

this chapter remain in full force and effect.

[62 FR 27693, May 21, 1997, as amended at 62 FR 53960, Oct. 17, 1997]

 

Sec. 1310.10 Removal of the exemption of drugs distributed under the

Food, Drug and Cosmetic Act.

 

(a) The Administrator may remove from exemption under

Sec. 1310.01(b)(28)(i)(D) any drug or group of drugs that the

Administrator finds is being diverted to obtain a listed chemical for

use in the illicit production of a controlled substance. In removing a

drug or group of drugs from the exemption the Administrator shall

consider:

(1) The scope, duration, and significance of the diversion;

(2) Whether the drug or group of drugs is formulated in such a way

that it cannot be easily used in the illicit production of a controlled

substance; and

(3) Whether the listed chemical can be readily recovered from the

drug or group of drugs.

(b) Upon determining that a drug or group of drugs should be removed

from the exemption under paragraph (a) of this section, the

Administrator shall issue and publish in the Federal Register his

proposal to remove the drug or group of drugs from the exemption, which

shall include a reference to the legal authority under which the

proposal is based. The Administrator shall permit any interested person

to file written comments on or objections to the proposal. After

considering any comments or objections filed, the Administrator shall

publish in the Federal Register his final order.

(c) The Administrator shall limit the removal of a drug or group of

drugs from exemption under paragraph (a) of this section to the most

identifiable type of the drug or group of drugs for which evidence of

diversion exists unless there is evidence, based on the pattern of

diversion and other relevant factors, that the diversion will not be

limited to that particular drug or group of drugs.

(d) Any manufacturer seeking reinstatement of a particular drug

product that has been removed from an exemption under paragraph (a) of

this section, may apply to the Administrator for reinstatement of the

exemption for that particular drug product on the grounds that the

particular drug product is manufactured and distributed in a manner that

prevents diversion. In determining whether the exemption should be

reinstated the Administrator shall consider:

(1) The package sizes and manner of packaging of the drug product;

(2) The manner of distribution and advertising of the drug product;

(3) Evidence of diversion of the drug product;

(4) Any actions taken by the manufacturer to prevent diversion of

the drug product; and

(5) Such other factors as are relevant to and consistent with the

public health and safety, including the factors described in paragraph

(a) of this section as applied to the drug product.

(e) Within a reasonable period of time after receipt of the

application for reinstatement of the exemption, the

 

[[Page 116]]

 

Administrator shall notify the applicant of his acceptance or non-

acceptance of his application, and if not accepted, the reason therefor.

If the application is accepted for filing, the Administrator shall issue

and publish in the Federal Register his order on the reinstatement of

the exemption for the particular drug product, which shall include a

reference to the legal authority under which the order is based. This

order shall specify the date on which it shall take effect. The

Administrator shall permit any interested person to file written

comments on or objections to the order. If any such comments raise

significant issues regarding any finding of fact or conclusion of law

upon which the order is based, the Administrator shall immediately

suspend the effectiveness of the order until he may reconsider the

application in light of the comments and objections filed. Thereafter,

the Administrator shall reinstate, revoke, or amend his original order

as he determines appropriate.

(f) Unless the Administrator has evidence that the drug product is

being diverted, as determined by applying the factors set forth in

paragraph (a) of this section, and the Administrator so notifies the

applicant, transactions involving a specific drug product will not be

considered regulated transactions during the following periods:

(1) While a bonafide application for reinstatement of exemption

under paragraph (d) of this section for the specific drug product is

pending resolution, provided that the application for reinstatement is

filed not later than 60 days after the publication of the final order

removing the exemption; and

(2) For a period of 60 days following the Administrator's denial of

an application for reinstatement.

(g) An order published by the Administrator in the Federal Register,

pursuant to paragraph (e) of this section, to reinstate an exemption may

be modified or revoked with respect to a particular drug product upon a

finding that:

(1) Applying the factors set forth in paragraph (a) of this section

to the particular drug product, the drug product is being diverted; or

(2) There is a significant change in the data that led to the

issuance of the final rule.

[60 FR 32461, June 22, 1995, as amended at 62 FR 13968, Mar. 24, 1997]

 

Sec. 1310.11 Reinstatement of exemption for drug products distributed

under the Food, Drug and Cosmetic Act.

 

(a) The Administrator has reinstated the exemption for the drug

products listed in paragraph (e) of this section from application of

sections 302, 303, 310, 1007, and 1008 of the Act (21 U.S.C. 822-823,

830, and 957-958), to the extent described in paragraphs (b), (c), and

(d) of this section.

(b) No reinstated exemption granted pursuant to 1310.10 affects the

criminal liability for illegal possession or distribution of listed

chemicals contained in the exempt drug product.

(c) Changes in exempt drug product compositions: Any change in the

quantitative or qualitative composition, trade name or other designation

of an exempt drug product listed in paragraph (d) requires a new

application for reinstatement of the exemption.

(d) The following drug products, in the form and quantity listed in

the application submitted (indicated as the ``date'') are designated as

reinstated exempt drug products for the purposes set forth in this

section:

 

Exempt Drug Products

----------------------------------------------------------------------------------------------------------------

Supplier Product name Form Date

----------------------------------------------------------------------------------------------------------------

[Reserved]........................... ....................... ....................... .......................

----------------------------------------------------------------------------------------------------------------

 

[60 FR 32462, June 22, 1995]

 

Sec. 1310.14 Exemption of drug products containing ephedrine and

therapeutically significant quantities of another active

medicinal ingredient.

 

(a) Any manufacturer of a drug product containing ephedrine in

combination with another active medicinal ingredient, the product

formulation of which is not listed in the compendiums set forth in Sec.

1310.01(b)(28)(i)(D)(1), may request that the Administrator exempt the

product as one which contains ephedrine together with a therapeutically

significant quantity of another active medicinal ingredient.

 

[[Page 117]]

 

(b) An application for an exemption under this section shall contain

the following information:

(1) The name and address of the applicant;

(2) The exact trade name of the drug product for which exemption is

sought;

(3) The complete quantitative and qualitative composition of the

drug product;

(4) A brief statement of the facts which the applicant believes

justify the granting of an exemption under this section; and

(5) Certification by the applicant that the product may be lawfully

marketed or distributed under the Food, Drug, and Cosmetic Act.

(6) The identification of any information on the application which

is considered by the applicant to be a trade secret or confidential and

entitled to protection under U.S. laws restricting the public disclosure

of such information by government employees.

(c) The Administrator may require the applicant to submit such

additional documents or written statements of fact relevant to the

application which he deems necessary for determining if the application

should be granted.

(d) Within a reasonable period of time after the receipt of a

completed application for an exemption under this section, the

Administrator shall notify the applicant of acceptance or non-acceptance

of the application. If the application is not accepted, an explanation

will be provided. The Administrator is not required to accept an

application if any of the information required in paragraph (b) of this

section or requested pursuant to paragraph (c) of this section is

lacking or not readily understood. The applicant may, however, amend the

application to meet the requirements of paragraphs (b) and (c) of this

section. If the application is accepted for filing, the Administrator

shall issue and publish in the Federal Register an order on the

application, which shall include a reference to the legal authority

under which the order is based. This order shall specify the date on

which it shall take effect. The Administrator shall permit any

interested person to file written comments on or objections to the

order. If any comments or objections raise significant issues regarding

any findings of fact or law upon which the order is based, the

Administrator shall immediately suspend the effectiveness of the order

until he may reconsider the application in light of the comments and

objections filed. Thereafter, the Administrator shall reinstate, revoke,

or amend the original order as deemed appropriate.

[60 FR 32462, June 22, 1995, as amended at 62 FR 13968, Mar. 24, 1997]

 

Sec. 1310.15 Exempt drug products containing ephedrine and

therapeutically significant quantities of another active

medicinal ingredient.

 

(a) The drug products containing ephedrine and therapeutically

significant quantities of another active medicinal ingredient listed in

paragraph (e) of this section have been exempted by the Administrator

from application of sections 302, 303, 310, 1007, and 1008 of the Act

(21 U.S.C. 822-3, 830, and 957-8) to the extent described in paragraphs

(b), (c), and (d) of this section.

(b) No exemption granted pursuant to 1310.14 affects the criminal

liability for illegal possession or distribution of listed chemicals

contained in the exempt drug product.

(c) Changes in drug product compositions: Any change in the

quantitative or qualitative composition of an exempt drug product listed

in paragraph (d) requires a new application for exemption.

(d) In addition to the drug products listed in the compendium set

forth in Sec. 1310.01(b)(28)(i)(D)(1), the following drug products, in

the form and quantity listed in the application submitted (indicated as

the ``date'') are designated as exempt drug products for the purposes

set forth in this section:

 

Exempt Drug Products Containing Ephedrine and Therapeutically Significant Quantities of Another Active Medicinal

Ingredient

----------------------------------------------------------------------------------------------------------------

Supplier Product name Form Date

----------------------------------------------------------------------------------------------------------------

[Reserved]........................... ....................... ....................... .......................

----------------------------------------------------------------------------------------------------------------

 

[60 FR 32463, June 22, 1995, as amended at 62 FR 13968, Mar. 24, 1997]

 

 

 

Back to DRUG POLICY TITLE PAGE

Back to Dan's main page

Last Reviewed: